The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.
Abstract
BACKGROUND: The blood coagulation system is activated in the acute phase of unstable angina and acute myocardial infarction. However, it remains unclear whether augmented function of the hemostatic mechanism serves only as a marker of the acute thrombotic episode or whether a hypercoagulable state persists for a prolonged period after clinical stabilization. METHODS AND RESULTS: We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FPA) in consecutive patients presenting with unstable angina (n = 81) or acute myocardial infarction (n = 32), respectively. At 6 months, plasma determinations were repeated in patients experiencing an uneventful clinical course (unstable angina, n = 57; myocardial infarction, n = 23). We quantitated the plasma levels of F1 + 2 and FPA in control patients with stable angina (n = 37) or healthy individuals (n = 32) who were matched for age and sex. The median plasma concentrations of F1 + 2 and FPA are significantly higher in patients presenting with unstable angina (F1 + 2, 1.08 nmol/L; FPA, 2.4 nmol/L) or acute myocardial infarction (F1 + 2, 1.27 nmol/L; FPA, 3.55 nmol/L) compared with patients with stable angina (F1 + 2, 0.74 nmol/L; FPA, 1.3 nmol/L; P < .0001) or healthy individuals (F1 + 2, 0.71 nmol/L; FPA, 0.80 nmol/L; P < .0001). At 6 months, the median plasma levels of F1 + 2 in patients exhibiting an uneventful clinical course did not differ from values obtained at admission (unstable angina, 1.26 versus 1.07 nmol/L, P = NS; myocardial infarction, 1.22 versus 1.29 nmol/L, P = NS), whereas the median plasma levels of FPA in the same two subpopulations were significantly reduced (unstable angina, 1.1 versus 2.9 nmol/L, P = .0003; myocardial infarction, 1.1 versus 3.0 nmol/L; P = .0028). CONCLUSIONS: During the acute phase of unstable angina and myocardial infarction, patients exhibit increased coagulation system activity. Over the next 6 months, patients with unstable angina or myocardial infarction experiencing an uneventful clinical course manifest a persistent hypercoagulable state with minimal generation of fibrin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Stratification and Survival after Myocardial Infarction
The Multicenter Postinfarction Research Group (1983) · New England Journal of Medicine · doi:10.1056/nejm198308113090602 · Cited by 1,602
Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,538
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 638
Natural history of angina pectoris in the Framingham study
Kannel, W. B., & Feinleib, M. (1972) · The American Journal of Cardiology · doi:10.1016/0002-9149(72)90624-8 · Cited by 554
Measurement of Fibrinopeptide A in Human Blood
Nossel, H. L., Yudelman, I., Canfield, R. E., Butler, V. P., Spanondis, K., Wilner, G. D., & Qureshi, G. D. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107749 · Cited by 531
Bauer, K., & Rosenberg, R. (1987) · Blood · doi:10.1182/blood.v70.2.343.343 · Cited by 389
Self-citationStatistics in Medicine: Calculating confidence intervals for some non-parametric analyses
Campbell, M. J., & Gardner, M. J. (1988) · BMJ · doi:10.1136/bmj.296.6634.1454 · Cited by 318
Fibrin and Fibrinogen-Related Antigens in Patients with Stable and Unstable Coronary Artery Disease
Kruskal, J. B., Commerford, P. J., Franks, J. J., & Kirsch, R. E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172201 · Cited by 265
Teitel, J., Bauer, K., Lau, H., & Rosenberg, R. (1982) · Blood · doi:10.1182/blood.v59.5.1086.1086 · Cited by 264
Self-citationBauer, K. A., Weiss, L. M., Sparrow, D., Vokonas, P. S., & Rosenberg, R. D. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113238 · Cited by 199
Self-citation
Cited by
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Antman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Fuster, V (1994) · Circulation · doi:10.1161/01.cir.90.4.2126 · Cited by 848
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 685
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Klein, W., Buchwald, A., Hillis, S. E., Monrad, S., Sanz, G., Turpie, A. G. G., van der Meer, J., Olaisson, E., Undeland, S., & Ludwig, K. (1997) · Circulation · doi:10.1161/01.cir.96.1.61 · Cited by 526
van Es, R. F., Jonker, J. J., Verheugt, F. W., Deckers, J. W., & Grobbee, D. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09409-6 · Cited by 423
Bertrand, M. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2301 · Cited by 410
Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)
Swahn, E., & Wallentin, L. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00486-4 · Cited by 354
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis
Anand, S. S. (1999) · JAMA · doi:10.1001/jama.282.21.2058 · Cited by 311
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
(1997) · The Lancet · doi:10.1016/s0140-6736(97)01180-x · Cited by 301
Intertwining of thrombosis and inflammation in atherosclerosis
Croce, K., & Libby, P. (2007) · Current Opinion in Hematology · doi:10.1097/00062752-200701000-00011 · Cited by 284
Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment
McCarthy, C. P., Vaduganathan, M., McCarthy, K. J., Januzzi, J. L., Bhatt, D. L., & McEvoy, J. W. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1086 · Cited by 268
Identification of Active Tissue Factor in Human Coronary Atheroma
Marmur, J. D., Thiruvikraman, S. V., Fyfe, B. S., Guha, A., Sharma, S. K., Ambrose, J. A., Fallon, J. T., Nemerson, Y., & Taubman, M. B. (1996) · Circulation · doi:10.1161/01.cir.94.6.1226 · Cited by 254
Metadata
- Authors
- Merlini, P. A., Bauer, K. A., Oltrona, L., Ardissino, D., Cattaneo, M., Belli, C., Mannucci, P. M., & Rosenberg, R. D.
- Venue
- Circulation
- Published
- 1994-07
- Volume
- 90
- Issue
- 1
- Pages
- 61-68
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2032105970
- Cited by
- 597
- References
- 18
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.